Published in TB and Outbreaks Week, July 10th, 1995
Pretreatment resistance to rifampin is not common in most countries, but it may become more prevalent due to the increasing use of rifampin-containing regimens for the treatment of tuberculosis.
The incidence of acquired resistance to rifampin was reported to have increased from 2.8 percent in 1983 to 37.3 percent in 1986. Additional treatment of such patients is usually difficult because available drugs are usually expensive, toxic, and sometimes not effective.
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of TB and Outbreaks Week